Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B59a5a4c69a19d8123c7b5ea08a6437b0> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B59a5a4c69a19d8123c7b5ea08a6437b0 NCIT_P378 "NCI" @default.
- B59a5a4c69a19d8123c7b5ea08a6437b0 type Axiom @default.
- B59a5a4c69a19d8123c7b5ea08a6437b0 annotatedProperty IAO_0000115 @default.
- B59a5a4c69a19d8123c7b5ea08a6437b0 annotatedSource NCIT_C175251 @default.
- B59a5a4c69a19d8123c7b5ea08a6437b0 annotatedTarget "An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon administration, CDK2 inhibitor PF-07104091 selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are frequently overexpressed in tumor cells. CDK2/cyclin E complex plays an important role in retinoblastoma (Rb) protein phosphorylation and the G1-S phase cell cycle transition. CDK2/cyclin A complex plays an important role in DNA synthesis in S phase and the activation of CDK1/cyclin B for the G2-M phase cell cycle transition." @default.